Erythrocyte Membrane Camouflaged Nanotheranostics for Optical Molecular Imaging‐Escorted Self‐Oxygenation Photodynamic Therapy
Small · 2024-08 · 20 (31)
DOI: 10.1002/smll.202309026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 13.03.2024. Verfasst von Yilin Wan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Nano Biomedicine and Engineering, Shanghai Engineering Research Center for Intelligent Diagnosis and Treatment Instrument, School of Sen…. Hauptthemen laut MEDLINE: Photochemotherapy, Erythrocyte Membrane, Theranostic Nanomedicine, Porphyrins. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shenzhen Science and Technology Program.
Abstract (Originalsprache)
Hypoxic tumor microenvironment (TME) hampers the application of oxygen (O 2 )‐dependent photodynamic therapy (PDT) in solid tumors. To address this problem, a biomimetic nanotheranostics (named MMCC@EM) is developed for optical molecular imaging‐escorted self‐oxygenation PDT. MMCC@EM is synthesized by encapsulating chlorin e6 (Ce6) and catalase (CAT) in metal–organic framework (MOF) nanoparticles with erythrocyte membrane (EM) camouflage. Based on the biomimetic properties of EM, MMCC@EM efficiently accumulates in tumor tissues. The enriched MMCC@EM achieves TME‐activatable drug release, thereby releasing CAT and Ce6, and this process can be monitored through fluorescence (FL) imaging. In addition, endogenous hydrogen peroxide (H 2 O 2 ) will be decomposed by CAT to produce O 2 , which can be reflected by the measurement of intratumoral oxygen concentration using photoacoustic (PA) imaging. Such self‐oxygenation nanotheranostics effectively mitigate tumor hypoxia and improve the generation of singlet oxygen ( 1 O 2 ). The 1 O 2 disrupts mitochondrial function and triggers caspase‐3‐mediated cellular apoptosis. Furthermore, MMCC@EM triggers immunogenic cell death (ICD) effect, leading to an increased infiltration of cytotoxic T lymphocytes (CTLs) into tumor tissues. As a result, MMCC@EM exhibits good therapeutic effects in 4T1‐tumor bearing mice under the navigation of FL/PA duplex imaging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Nano Biomedicine and Engineering, Shanghai Engineering Research Center for Intelligent Diagnosis and Treatment Instrument, School of Sensing Science and Engineering, School of Electronic Information and Ele…
- Marshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenz…
ORCID-Profile: Peng Huang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Shenzhen Science and Technology Program
- Standard Project of Shanghai Science and Technology Commission
- Instrument Project of Shanghai Science and Technology Commission
- Shenzhen Medical Research Fund
Zitieren
APA
Wan, Y., Li, C., Fu, L. H., Feng, T., Zhang, Y., Li, Y., Lin, J., Huang, P., & Cui, D. X. (2024). Erythrocyte Membrane Camouflaged Nanotheranostics for Optical Molecular Imaging‐Escorted Self‐Oxygenation Photodynamic Therapy. Small, 20(31). https://doi.org/10.1002/smll.202309026
Vancouver
Wan Y, Li C, Fu LH, Feng T, Zhang Y, Li Y, et al. Erythrocyte Membrane Camouflaged Nanotheranostics for Optical Molecular Imaging‐Escorted Self‐Oxygenation Photodynamic Therapy. Small. 2024;20(31). doi:10.1002/smll.202309026
BibTeX
@article{Wan2024,
author = {Wan, Yilin and Li, Chunying and Fu, Lian-Hua and Feng, Ting and Zhang, Yifan and Li, Youyan and Lin, Jing and Huang, Peng and Cui, Da-Xiang},
title = {Erythrocyte Membrane Camouflaged Nanotheranostics for Optical Molecular Imaging‐Escorted Self‐Oxygenation Photodynamic Therapy},
journal = {Small},
year = {2024},
volume = {20},
number = {31},
doi = {10.1002/smll.202309026}
}
EUVIMED